4.3 Article

Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C -> T mutation

Journal

HAEMOPHILIA
Volume 15, Issue 1, Pages 91-100

Publisher

WILEY
DOI: 10.1111/j.1365-2516.2008.01792.x

Keywords

bleeding phenotype; carrier; haemophilia B

Categories

Ask authors/readers for more resources

The aim of this study was to characterize the variability of bleeding phenotype and its association with plasma factor IX coagulant activity (FIX:C) in haemophilia B carriers in a large Amish pedigree with a unifying genetic mutation, C-to-T transition at base 31008 of the factor IX gene (Xq27.1-27.2). A cross-sectional survey of haemophilia B carriers included a multiple choice questionnaire evaluating symptoms of mucocutaneous bleeding, joint bleeding and bleeding after haemostatic stress [menstruation, postpartum haemorrhage (PPH), dental extractions and invasive surgeries]. Severity of bleeding was graded as 0 to 4, 0 being no bleeding whereas 4 being severe bleeding. Association between total bleeding scores and the FIX:C was evaluated. Sixty-four haemophilia B carriers participated in this study. Median age: 18 years (range 1-70 years); median bleeding score: 1 (range 0-8). Besides PPH, isolated symptoms of bruising, epistaxis, menorrhagia and postsurgical bleeding including dental extraction were not associated with lower FIX:C. Bleeding score >= 3 was associated with involvement of at least two bleeding sites and a lower mean FIX:C of 42 +/- 10.3% (95% CI 36.4-47.7) while a score > 3 had involvement of <= 2 sites and higher mean FIX:C of 54.9 +/- 21.5% (95% CI 49-61), P = 0.005. Subcutaneous haematoma formation and bleeding after haemostatic stress requiring treatment were associated with bleeding scores >= 3. Phenotypic variability existed among the carriers of haemophilia B who belonged to a single pedigree carrying a single unifying mutation. The utility of bleeding scores to define bleeding phenotype precisely in haemophilia B carriers needs further evaluation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism

Tzu-Fei Wang, Amanda P. Waller, Ella Lin, Lai Wei, Abigail Bartosic, Ken Riedl, Bryce A. Kerlin

Summary: This pilot study aimed to investigate the effects of statins in addition to anticoagulation in patients with acute VTE, but found that statins did not significantly reduce thrombin generation. Although atorvastatin significantly reduced LDL levels at 3 months, it had no impact on d-dimer or high-sensitivity-C reactive protein. The study was terminated early due to low recruitment rate and barriers to enrollment.

BLOOD COAGULATION & FIBRINOLYSIS (2021)

Article Hematology

Factor V east Texas variant causes bleeding in a three-generation family

Julie A. Peterson, Sweta Gupta, Nicholas D. Martinez, Brandon Hardesty, Susan A. Maroney, Alan E. Mast

Summary: This study diagnosed a family with Factor V east Texas bleeding disorder and identified the FVET variant associated with bleeding symptoms. The research suggests that elevated plasma TFPI alpha may be the primary cause of bleeding and effective therapies could include the use of an anti-TFPI antibody or factor VIIa. Increased awareness and testing for bleeding disorders related to F5 exon 13 variants and elevated plasma TFPI are necessary.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Article Multidisciplinary Sciences

Selective modulator of nuclear receptor PPARγ with reduced adipogenic potential ameliorates experimental nephrotic syndrome

Claire Bryant, Galen Rask, Amanda P. Waller, Amy Webb, Marina R. Galdino-Pitta, Angelica A. Amato, Rachel Cianciolo, Rajgopal Govindarajan, Brian Becknell, Bryce A. Kerlin, Francisco A. R. Neves, Alessia Fornoni, Shipra Agrawal

Summary: The study found that selective modulation of PPAR gamma by GQ-16 is more effective in reducing proteinuria, NS associated comorbidities, and adipogenic side effects compared to pioglitazone.

ISCIENCE (2022)

Article Hematology

Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial

Riten Kumar, Amy L. Dunn, Jane E. Schneiderman, Anne Gonzales, Vanessa Bouskill, Pamela Widener, Joseph Stanek, Fred G. Pluthero, Amanda Waller, Cristina Tarango, Sanjay Ahuja, Bryce A. Kerlin, Walter H. A. Kahr, Margaret L. Rand, David Lillicrap, Manuel Carcao

Summary: Persons with mild hemophilia A can improve their coagulation function by using intranasal desmopressin prior to sports participation, although the duration of improvement is short. Moderate-intensity aerobic exercise can also improve coagulation function. Combining exercise with desmopressin treatment can achieve better results.

BLOOD (2022)

Article Physiology

Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity

Ajay Medipally, Min Xiao, Laura Biederman, Anjali A. Satoskar, Iouri Ivanov, Brad Rovin, Samir Parikh, Bryce A. Kerlin, Sergey Brodsky

Summary: The study aimed to investigate the role of PAR-1 in the pathogenesis of ARN. Through observations and evaluations of 5/6NE rats treated with different agents, it was found that both activation and blockage of PAR-1 led to glomerular hematuria and subsequent acute tubular epithelial cell injury.

PHYSIOLOGICAL REPORTS (2022)

Meeting Abstract Hematology

Hypoalbuminemia Increases Clot Fibrin Network Density and Impairs Fibrinolysis during Glomerular Proteinuria

Amanda P. Waller, Katelyn J. Wolfgang, Zachary S. Stevenson, Bryce A. Kerlin

BLOOD (2022)

Meeting Abstract Hematology

Cardiovascular Disease Prevention in Persons with Hemophilia

Brandon Hardesty, Joel Bowen, Suman L. Sood, Craig M. Kessler, Maissaa Janbain, Miguel Escobar, Doris Quon

BLOOD (2022)

Review Hematology

Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review

Amy D. Shapiro, Brandon M. Hardesty, Flora Peyvandi, Alfonso Iorio

Summary: Life expectancy for persons with hemophilia has increased due to advances in treatment, but they are now more likely to be affected by conditions associated with aging. This study analyzed the prevalence of bleeding and thrombotic events in hemophilia populations compared to the general population. The results showed consistently higher rates of bleeding events in hemophilia populations, while the prevalence of arterial thrombosis varied.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2023)

Article Cardiac & Cardiovascular Systems

Prognostic Value of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Predicting Venous Thromboembolism in Children With Lymphoma

Maren Beall, Kyra Deep, Nguyen K. K. Tram, Mahboubeh Nabavinia, Sarah A. A. Janse, Ting-Heng Chou, Dariya Hardisky, Adam J. J. Bobbey, Bryce A. A. Kerlin, Anthony N. N. Audino, Mitchel R. R. Stacy

Summary: The purpose of this study was to evaluate the prognostic value of fluorine-18-fluorodeoxyglucose PET/CT imaging of venous inflammation for predicting venous thromboembolism (VTE) occurrence in pediatric, adolescent, and young adult patients with lymphoma. The study found that PET/CT imaging could detect venous inflammation and it was associated with the occurrence of VTE.

CIRCULATION-CARDIOVASCULAR IMAGING (2023)

Article Public, Environmental & Occupational Health

Increasing Visibility of Sickle Cell Disease in Indiana: Establishing Baseline Prevalence Using Integrated Data From Multiple Sources

Amanda I. I. Okolo, Seethal A. A. Jacob, Brian E. E. Dixon, Nimish R. R. Valvi, Isaac A. A. Janson, Brandon R. R. Hardesty

Summary: The Indiana Sickle Cell Data Collection (IN-SCDC) program aims to provide timely, reliable, and locally relevant information on the sickle cell disease (SCD) population in Indiana to inform public health interventions, research, and policy development. Using an integrated data collection approach, the program identified 1695 people living with SCD in Indiana during the study period, with a prevalence of 24.7 cases per 100 000 people and a higher prevalence among Black or African American individuals.

PUBLIC HEALTH REPORTS (2023)

Article Hematology

Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study

Michael D. Tarantino, Brandon Hardesty, Ara Metjian, Thomas L. Ortel, Jie Chen, Kayode Badejo, Alice Ma, Adam Cuker, Anita Rajasekhar, Kenneth D. Friedman, Maissaa Janbain

Summary: This study aimed to provide long-term real-world safety and effectiveness data for rpFVIII in the management of AHA bleeding episodes. The results showed that 80.3% of bleeds treated with rpFVIII resolved effectively. No new safety issues were identified.

HAEMOPHILIA (2023)

Article Oncology

Pediatric arterial thrombosis: A single-institution cohort study of patient characteristics and thrombosis outcomes

Eman Abdelghani, Shreya Agarwal, Joseph Stanek, Amanda Sankar, Bryce A. Kerlin, Vilmarie Rodriguez

Summary: This study aims to describe treatment patterns and outcomes in pediatric patients with arterial thrombosis (AT) and explore predictors for complete thrombus resolution or long-term complications. The results showed that the duration of anticoagulation varied greatly, and a significant proportion of patients developed long-term sequelae secondary to arterial insufficiency. In addition, patients with infection-associated AT were more likely to have long-term complications.

PEDIATRIC BLOOD & CANCER (2023)

Meeting Abstract Hematology

DIRECT ORAL ANTICOAGULANTS IN PROTEINURIC KIDNEY DISEASE

Bryce Kerlin

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Hematology

Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence

Lone Hvitfeldt Poulsen, Bryce A. Kerlin, Giancarlo Castaman, Angelo Claudio Molinari, Marzia Menegatti, Diane Nugent, Sohan Dey, May-Lill Garly, Manuel Carcao

Summary: The study demonstrates that long-term rFXIII-A(2) prophylaxis is well tolerated in patients with FXIII-A CD. There were no spontaneous bleeds, low treatment-requiring bleeding rate, and successful treatment of bleeds with rFXIII-A(2).

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

Article Hematology

Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists

Vilmarie Rodriguez, Joseph Stanek, Bryce A. Kerlin, Amy L. Dunn

Summary: Recent clinical trials have shown the safety and efficacy of direct oral anticoagulants (DOACs) for the treatment of venous thromboembolism (VTE) in pediatric patients. However, there is limited evidence on the use of andexanet alfa and prothrombin complex concentrates (PCC) for reversing the effects of direct oral factor Xa inhibitors (DXIs) in this population. A survey of pediatric hematology experts revealed that some would consider andexanet alfa and PCC as potential options for managing life-threatening bleeding in children on DXIs, but further investigation is needed.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2022)

No Data Available